Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial)

Journal of the National Cancer Center · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles